Gaucher病治疗市场份额，规模，趋势，行业分析报告，通过疾病类型（I型，II型，III型）;通过治疗型（酶替代疗法（ERT），底物还原治疗（SRT））;按地区，细分和预测，2017年 - 2025年

Report Summary

The global gaucher disease treatment market is estimated to grow at a CAGR of 2.8% between 2018 to 2025. Gaucher disease is one of the most common liposomal storage disorders which is caused due to the not having enough glucocerebrosidase that is an important enzyme which breaks down the fatty chemicals namely glucocerebroside, that builds up Gaucher cells in the spleen, liver, and bone marrow. It is one the rare disease that is majorly found in the population from Ashkenazi Jewish.

这种疾病主要是脾脏或肝脏，疲劳，贫血，骨疼痛和骨折，易刷牙和出血等症状。有各种类型的Gaucher病，即I型，II型，III型。I型是最常见的Gaucher病类型，不会影响个人的神经系统。这种疾病，在Ashkenazi犹太人中影响了850人中的1个，而非阿什肯尼亚犹太人有1次40,000人。

North America Gaucher Disease Treatment Market Share By Treatment type,
2017 - 2025

Know more about this report:请求样本页面

The Gaucher disease treatment market is primarily driven by the increasing number of drug approvals by the U.S. FDA which promotes the new approach for developing new drugs by the key leaders operating in the market. Additionally, the collaboration between various biopharmaceutical and research centers to also boost the market growth in the coming years. Furthermore, the government initiatives to promote the awareness about Gaucher disease. For instance, the European Gaucher Alliance recently launched a Gaucher Awareness day aiming at creating awareness about this disease in the population. However, the higher number of ongoing researches across the globe would limit the growth of the Gaucher Disease market.

Segment Analysis

The global Gaucher disease treatment market is segmented on the basis of disease type, and treatment type, and geography. On the basis of disease type, the Gaucher disease treatment market is segmented as type I, type II, and type III. The type I Gaucher disease is observed to be the dominating market segment in the market, owning to the increasing number of people suffering from type I disease across the globe. According to Erad Therapeutics Inc., approximately 7,000 people are suffering from Type I Gaucher disease out to 8,000 people that suffer from Gaucher disease in the U.S. driving this segments market during the forecast period.

Based on treatment type, the Gaucher disease treatment market is segmented as Enzyme Replacement Therapy (ERT), and Substrate Reduction Treatment (SBT). The enzyme replacement therapy to be the dominating segment in the market. This treatment market is primarily driven by its increased adoption across the globe for treating Gaucher disease, and higher awareness for using ERT. Additionally, the higher number of FDA approved drugs in the ERT to also add on the growth of this segment.

区域分析

通过地理，全球瓦氏疾病治疗市场被分成五个主要地区，北美，欧洲，亚太地区，拉丁美洲和中东和非洲。北美洲，在戈什疾病治疗市场中拥有最大的市场份额，拥有越来越多的人患有这种疾病，未解释的临床需求，并在未来几年内使用有效治疗方案的认识。此外，以色列在预测期间是一个明显的市场，这是患有这种疾病的人数最快的预测期。

Competitive Analysis

Some of the major key players operating in global gaucher disease treatment market are Sonafi (Genzyme Corporation), Pfizer Inc., Acetelion Pharmaceutical (J&J Ltd.), Shire Human Genetics Therapies, Inc., Erad Therapeutic Inc., and JCR Pharmaceuticals Co Ltd.